NIJMEGEN, Netherlands, Oct. 25, 2022 /PRNewswire/ — Symeres, a number one global drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), today declares the acquisition of Exemplify BioPharma (or “Exemplify”), a US based CRO that gives integrated drug development services in Process & Analytical Chemistry and Formulation Development to pharmaceutical and biotech partners.
Keensight Capital, one among the leading private equity managers dedicated to pan-European Growth Buyout investments1 and the bulk shareholder in Symeres, has worked along with the management teams of each firms to facilitate this business combination.
Exemplify BioPharma, based in Cranbury, Latest Jersey (US), is a provider of high-quality integrated end-to-end small molecule Chemistry Manufacturing and Controls (CMC) services to pharmaceutical and biotech partners. The corporate offers functional expertise and consultancy services in Process Chemistry, Analytical Chemistry, and Formulation Development for a successful transition of programs from late-stage lead optimization through candidate selection to first-in-human. Exemplify employs 20 people, of which the bulk are Ph.D-level scientists. The corporate will remain under the present management of co-founders: Yadan Chen, Chief Executive Officer, and Dr. Paul O’Shea, Chief Scientific Officer.
This acquisition further strengthens Symeres’ strategic foothold within the US, where the corporate already generates about 50% of its revenues. Exemplify operates from its recent state-of-the-art 18,600 sq. ft. facility in Latest Jersey. Its functional expertise in Process & Analytical Chemistry and Formulation Development represents a highly synergistic combination with Symeres capabilities and repair offering.
Exemplify BioPharma is Symeres’ second acquisition within the US this 12 months, following the acquisition of Organix Inc., an organic chemistry services provider based within the Boston area specialized in lipids addressing the mRNA therapeutics and vaccines market.
Yadan Chen, CEO of Exemplify BioPharma, stated: “We’re proud to see Exemplify BioPharma’s scientific expertise and strategic location in North America recognized and change into a part of the Symeres family. Symeres is a trusted partner that shares our values and business philosophy of strong customer focus. Exemplify BioPharma’s recent move to our recent and bigger state-of-the-art facility, and the mix with a worldwide business like Symeres, will allow us to raised serve our clients under one roof. We stay up for accelerating our growth together.“
Dr. Eelco Ebbers, Co-founder and CEO of Symeres, stated: “We’re pleased to welcome Exemplify BioPharma into the group. Exemplify has a wonderful track record of supporting the event needs of North American biotech firms through their experience and outstanding laboratory-based science. This acquisition, following the addition of Organix earlier this 12 months and our investment plans for all of our R&D facilities, is an additional tangible demonstration of Symeres’ strategy of constructing a number one mid-sized transatlantic pharmaceutical R&D service provider for our clients around the globe.”
Amit Karna, Partner at Keensight Capital, added: “Following the recent acquisition of Organix within the Boston area, the addition of Exemplify BioPharma in Latest Jersey marks one other milestone in Symeres’ technique to construct a really transatlantic business, serving the biopharma industry globally. The scientific and cultural fit of Exemplify BioPharma inside the group is great. Keensight Capital is delighted to support Symeres on this exciting acquisition.“
Saola Healthcare Partners acted as strategic and financial advisor, Goodwin Procter LLP as legal advisor, and Alvarez & Marsal as financial due diligence advisor to Symeres.
Symeres is a number one transatlantic small molecule CRO & CDMOs, providing R&D services from preclinical drug discovery to Phase I and II clinical stage drug development and manufacturing, to major pharmaceutical and biotechnology firms across the globe. Its highly specialized services include integrated small molecule optimization efforts, complex synthetic chemistry, route scouting & API (Lively Pharmaceutical Ingredient) synthesis as much as GMP production, solid state chemistry and ADME-Tox services.
Symeres is headquartered in the Netherlands and employs around 600 people worldwide, lots of whom are Ph.D scientists. The corporate has operating sites in the Netherlands, the Czech Republic, Finland, and the US. Over several many years, the corporate has enjoyed a powerful growth trajectory, with revenues rising organically at a double-digit rate each year, further complemented by strategic acquisitions. Proforma for the mixing of Exemplify, the group expects to achieve c.€95 million in annual revenues.
Symeres is a number one mid-sized transatlantic Contract Research Organization for drug discovery and development needs, with around 600 employees operating from 7 sites in the Netherlands, the Czech Republic, Finland, and the US. The corporate offers best-in-class solutions for drug discovery and drug development for small molecules and beyond. Their services span from preclinical hit finding all of the technique to the delivery of early clinical phase drug substance API. Symeres blends a deep scientific knowledge base with creativity and problem-solving skills to deliver quality results that clients need.
About Exemplify BioPharma
Exemplify BioPharma is a Global Partnership Organization (GPO), founded in 2015, and based in Latest Jersey (US). It’s a fast-growing company with c.20 employees that serves scientists in biopharma firms everywhere in the world, providing high-quality expertise in CMC (Chemistry, Manufacturing, Controls) chemistry services for drug development. The corporate is led by Yadan Chen, CEO and Dr. Paul O’Shea, CSO.
About Keensight Capital
Keensight Capital, one among the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. For 20 years, Keensight Capital’s team of seasoned professionals has leveraged their knowledge of investment and growth industries to speculate for the long run in profitable firms with high growth potential and revenues within the range of €10 million to €400 million. Drawing on its expertise within the Technology and Healthcare sectors, Keensight identifies one of the best investment opportunities in Europe and works closely with management teams to develop and achieve their strategic vision.
Keensight Capital’s success has earned it a Gold Award from the Private Equity Exchange & Awards annually for the last five consecutive years and, as well as, the Best European Growth Private Equity Fund.
Eelco Ebbers – [email protected] – +31 6 21 28 33 23
Yadan Chen – [email protected] – +1 (732) 500-3208
Timothy Lee – [email protected] – +44 20 4558 9021
Evelyn McCormack / George Underwood [email protected] – +44 203 928 6900
Ruben Cardol – [email protected] – +31 6 55 35 84 27
1 Growth Buyout: investment in profitable, private firms experiencing strong growth, in minority or majority positions, with or without leverage, using a versatile approach tailored to the needs of individual entrepreneurs, with the intention to finance organic growth projects, acquisition strategies or provide historic shareholders with liquidity.